On January 4, 2021 Paul J. Diaz, president and CEO of Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in precision medicine and molecular diagnostics, reported that it will discuss the company’s transformation and growth initiatives at the 39th Annual J.P. Morgan Healthcare Conference at 2:50 p.m. EST on January 11, 2021 (Press release, Myriad Genetics, JAN 4, 2021, View Source [SID1234573415]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mr. Diaz will focus on key opportunities to fulfill the company’s mission of improving patient lives by unlocking the power of precision medicine and helping healthcare providers and payers prevent, diagnose and treat disease through the company’s genetic insights. The presentation will be available via a live audio webcast accessible at the following direct link or through the investor information section of Myriad’s website at www.myriad.com.